|RYTM Rhythm Pharma IPO'ed today and popped up near double from offer price. which is unusual for a bio-ipo. It seems Rocket Pharma (itek) is in same type of area as Rhythm (drugs to treat rare conditions)... thus it appears "people in the know" bought ITEK like crazy in last 2 weeks knowing RYTM was doing ipo. |
"Rhythm is a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. Rhythm supports The Genetic Obesity Project (www.GeneticObesity.com), which is dedicated to improving the understanding of severe obesity that is caused by specific genetic defects. The company is based in Boston, MA."
"Rocket is a leader in developing first-in-class gene therapies for patients with rare genetic diseases with complex and challenging treatment options, such as bone marrow and organ transplants"